Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Atea Pharmaceuticals excels in Q3 with promising HCV program

Atea Pharmaceuticals demonstrated strong performance in Q3 2024, with promising trial results and a solid financial position.
The company's HCV program shows great potential for addressing unmet medical needs and driving future growth.
While facing challenges in trial design and market competition, Atea remains confident in its ability to innovate and succeed in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February 19-22, 2023 in Seattle, Washington.

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET.

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA.

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29 at 9:40 a.m. ET.

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade

The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - CEO and Founder John Vavricka - CCO Janet Hammond - CDO Andrea Corcoran - CFO and Executive President, Legal Conference Call Participants Hannah Adeoye - JPMorgan Matthew Harrison - Morgan Stanley Umer Raffat - Evercore Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Conference Call.

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call Transcript

Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2022, and to provide a business update.

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.

Atea (AVIR) Dengue Candidate Gets Fast Track Designation

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer & Executive President of Legal John Vavricka - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2022 Financial Results Conference Call.

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2022 Results - Earnings Call Transcript

Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business update.

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals together with other members of the Atea management team, will participate in the William Blair Biotech Focus Conference.

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and update at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:00 a.m. ET.

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Jean-Pierre Sommadossi - Founder & CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO & EVP, Legal John Vavricka - Chief Commercial Officer Jonae Barnes - SVP, IR & Corporate Communications Conference Call Participants Hannah Colgan - JPMorgan Umer Raffat - Evercore Nik Gasic - SVB Securities Jonathan Miller - Evercore Operator Good morning, and welcome to the Atea Pharmaceuticals First Quarter 2022 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode to prevent any background noise.

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q1 2022 Results - Earnings Call Transcript

New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory)

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Bemnifosbuvir Demonstrated Favorable Overall Nonclinical Safety Profile, Including Lack of Reproductive and Development Toxicity in Animal Models Bemnifosbuvir Demonstrated Favorable Overall Nonclinical Safety Profile, Including Lack of Reproductive and Development Toxicity in Animal Models

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting

Atea Pharmaceuticals, Inc. (AVIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains?

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q4 2021 Results - Earnings Call Transcript

News for Atea Pharmaceuticals Stock (AVIR)